<table>
<thead>
<tr>
<th>STATUS</th>
<th>DOCUMENT REVISION</th>
<th>EFFECTIVE DATE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>2.0</td>
<td>March 1, 2012</td>
<td>Initial version Uniform Managed Care Manual Chapter 2.2, &quot;Uniform Managed Care Pharmacy Claims Manual.&quot; This chapter applies to contracts issued as a result of HHSC RFP numbers 529-06-0293, 529-08-0001, 529-10-0020, and 529-12-0002.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.1</td>
<td>March 20, 2013</td>
<td>Sections III and IV are modified to add clarifying language to the T.A.C. references. Section V is modified to add clarifying language. Section VI is modified to add clarifying language, to clarify Sub-Section D requirements for HRSA 340b claims and interest payments, and to add Sub-Section F &quot;Medicaid Wrap-around Services for Outpatient Drugs and Biological Products&quot;. Section IX &quot;Interest Payments&quot; is added. Section X is modified to add clarifying language. Attachment A &quot;Medicare Part B and D Claims Processing Flowchart&quot; is added. Attachment B &quot;Commercial COB Cost Avoidance Processing Flowchart&quot; is added.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.2</td>
<td>March 1, 2014</td>
<td>Section VI.A. is modified to remove language regarding Medicaid as the secondary payor for STAR Health. Section VI Sub-Section G &quot;Flu Vaccines Provided in a Pharmacy&quot; is added. This chapter applies to contracts issued as a result of HHSC RFP numbers 529-06-0293, 529-08-0001, 529-10-0020, 529-12-0002, and 529-13-0042.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.3</td>
<td>August 15, 2014</td>
<td>Section V. is modified to reference the MCO’s relevant Contract. Section VI.D. is modified to clarify HRSA 340B claims submission codes. Section VIII. is modified to reference performance requirements and timeframes described in the Contract.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.4</td>
<td>October 15, 2014</td>
<td>Revision 2.4 applies to contracts issued as a result of HHSC RFP numbers 529-06-0293, 529-08-0001, 529-10-0020, 529-12-0002, and 529-13-0042; and to Medicare-</td>
</tr>
</tbody>
</table>
## DOCUMENT HISTORY LOG

<table>
<thead>
<tr>
<th>STATUS¹</th>
<th>DOCUMENT REVISION²</th>
<th>EFFECTIVE DATE</th>
<th>DESCRIPTION³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revision</td>
<td>2.5</td>
<td>January 15, 2015</td>
<td>Medicaid Plans (MMPs) in the Dual Demonstration. Section I. is modified to add the Medicare-Medicaid Dual Demonstration.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.6</td>
<td>October 1, 2015</td>
<td>Revision 2.6 applies to contracts issued as a result of HHSC RFP numbers 529-08-0001, 529-10-0020, 529-12-0002, 529-13-0042, 529-13-0071, and 529-15-0001; and to Medicare-Medicaid Plans (MMPs) in the Dual Demonstration. Section I. is modified to add the STAR Kids Program. Section VI. E. is modified to change the section name from “Medicaid Wrap-Around Services for Outpatient Drugs and Biological Products” to “Dual Eligible Members Medicaid Prescription Coverage for Outpatient Drugs and Biological Products” and update the requirements. Attachment A “Medicare Part B and D Claims Processing Flowchart” is deleted. Attachment B “Commercial COB Cost Avoidance Processing Flowchart” is renamed “COB Cost Avoidance Processing Flowchart” and re-lettered as Attachment A.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.7</td>
<td>March 1, 2016</td>
<td>Section VI. G. “Covered Drugs Under Non-Risk Payment” is added. Attachment A “COB Cost Avoidance Processing Flowchart” is modified to add an exemption for family planning drugs.</td>
</tr>
<tr>
<td>Revision</td>
<td>2.8</td>
<td>November 1, 2016</td>
<td>Section VI. D. &quot;Health Resources Services Administration (HRSA) 340B&quot; is modified to update the policy language. Section VI. E. “Dual Eligible Members Medicaid Prescription Coverage for Outpatient Drugs and Biological Products” is modified to add references to Attachments B and C. Section VI. H. &quot;Psychotropic Medication Utilization Review (PMUR)&quot; is added.</td>
</tr>
</tbody>
</table>
### DOCUMENT HISTORY LOG

<table>
<thead>
<tr>
<th>STATUS¹</th>
<th>DOCUMENT REVISION²</th>
<th>EFFECTIVE DATE</th>
<th>DESCRIPTION³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Section VI. I. &quot;Managed Care Clinical Prior Authorization Criteria Implementation&quot; is added.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attachment B. &quot;Medicare Part B Pharmacy Claims Processing&quot; is added.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Attachment C. &quot;Medicare Part D Pharmacy Claims Processing&quot; is added.</td>
</tr>
</tbody>
</table>

¹ Status should be represented as “Baseline” for initial issuances, “Revision” for changes to the Baseline version, and “Cancellation” for withdrawn versions.

² Revisions should be numbered according to the version of the issuance and sequential numbering of the revision—e.g., “1.2” refers to the first version of the document and the second revision.

³ Brief description of the changes to the document made in the revision.
TABLE OF CONTENTS

I. APPLICABILITY OF CHAPTER 2.2 ................................................................. 5
II. PURPOSE .............................................................................................................. 5
III. STATUTORY AND REGULATORY AUTHORITY ...................................... 5
IV. INFORMATIONAL RESOURCES ................................................................. 5
V. PHARMACY CLAIMS DEFINITIONS ....................................................... 6
VI. PHARMACY CLAIMS PROCESSING REQUIREMENTS ............................ 7
VII. MESSAGES TO PHARMACIES ............................................................... 14
VIII. PERFORMANCE REQUIREMENTS AND TIMEFRAMES ....................... 14
IX. INTEREST PAYMENTS ................................................................................. 14
X. HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) COMPLIANCE ............................................................................................................ 15
Attachment A – COB Cost Avoidance Processing Flowchart ......................... 16
Attachment B - Medicare Part B Pharmacy Claims Processing .................... 17
Attachment C - Medicare Part D Pharmacy Claims Processing .................... 18
I. APPLICABILITY OF CHAPTER 2.2

This chapter applies to Managed Care Organizations (MCOs) participating in the STAR, STAR+PLUS (including the Medicare-Medicaid Dual Demonstration), CHIP, STAR Kids, and STAR Health Programs. In this chapter, references to “CHIP” or the “CHIP Managed Care Program(s)” apply to the CHIP Program. References to “Medicaid” or the “Medicaid Managed Care Program(s)” apply to the STAR, STAR+PLUS, STAR Kids, and STAR Health Programs. The term “MCO” may include health maintenance organizations (HMOs), exclusive provider organizations (EPOs), insurers, Medicare-Medicaid Plans (MMPs), and any other entities licensed or approved by the Texas Department of Insurance. The requirements in this chapter apply to all programs, except where noted.

II. PURPOSE

This chapter establishes pharmacy claims processing requirements and timelines, to the extent that they differ from the requirements and timelines in Chapter 2.0, “Uniform Managed Care Claims Manual.” This chapter should be read in conjunction with Chapter 2.0, and unless otherwise noted in this chapter, all provisions of Chapter 2.0 apply to pharmacy claims.

III. STATUTORY AND REGULATORY AUTHORITY

Statutory and regulatory authority for this chapter includes the following, without limitation.

- All authorities cited in Chapter 2.0, “Uniform Managed Care Claims Manual;”
- 1 Tex. Admin. Code Chapter 353, Subchapter J, “Outpatient Pharmacy Services” (Medicaid); and

IV. INFORMATIONAL RESOURCES

- Resources listed in Chapter 2.0, “Uniform Managed Care Claims Manual;” and
V. PHARMACY CLAIMS DEFINITIONS

1. **Automated Prior Authorization Request:** A claim adjudication process applied by the MCO that automatically evaluates whether a submitted pharmacy claim meets Prior Authorization criteria (e.g., drug history shows previous filling of preferred drug, client has specific diagnosis), when the data exist, thereby allowing the claim to be adjudicated as payable without the prescriber’s intervention.

2. **Clean Claim:** Refer to the Contract’s definition of “Clean Claim.” In addition, a Clean Pharmacy Claim must meet all requirements for accurate and complete data as defined in the applicable *NCPDP Post-Adjudication Companion Guide* and HHSC’s *Encounter Submission Guidelines*.

3. **Cost Avoidance:** A coordination of benefits model for pharmacy claims that ensures compliance with 42 C.F.R. Subpart D, Chapter 433. The cost avoidance model checks for a client’s other known insurance at the point of sale, preventing the MCO from paying a claim until the pharmacy attempts to obtain payment from the client’s third-party insurance. The elements of Cost Avoidance include the following.
   - Determination that member has other prescription drug coverage through a third-party insurer.
   - Sending verified drug insurance eligibility and insurer information to the pharmacy point-of-sale system.
   - If member has other insurance, deny claim at point-of-sale and provide pharmacy with the third-party billing information so they can submit the claim to them.
   - Continue to reject the claim until billing to all other payors has been attempted.
   - If the pharmacy submits it to the third party insurer and it is denied, the MCO may pay the claim, depending on the reason for denial.
   - Continue covering co-pays and deductibles for members with third party insurance.
   - Provide a toll-free number for members and providers to call to correct mistakes in third party insurance information so that the point-of-sale claims system will pay correctly (e.g., can use existing member or provider hotlines for this purpose).

4. **D.Ø Standard:** The most recent version of the National Council of Prescription Drug Program (NCPDP) Telecommunication Standard.
5. **Rejected Claim**: A claim filed with the MCO or its Subcontracted Claims Processor for pharmacy services rendered to a patient and the claim has been denied or not accepted for adjudication and payment. A rejected claim could be due to, but is not limited to the following situations: a patient was not a Member of the MCO at the time of service, a claim was filed with the MCO in error (wrong carrier), or the MCO is not responsible for Processing the claim but the claim is for a Member of the MCO as of the date of service.

Additional definitions are found in the MCO's relevant Contract and Chapter 2.0 of the Uniform Managed Care Manual (UMCM).

VI. PHARMACY CLAIMS PROCESSING REQUIREMENTS

A. **Pharmacy Claim Processing and Payment Requirements**

Clean Claims for outpatient pharmacy benefits must be adjudicated no later than: (1) 18 days after receipt if submitted electronically, or (2) 21 days after receipt if submitted non-electronically. Once a Clean Claim is received for a pharmacy claim, the MCOs are required, within the periods described above, to: (1) pay the total amount of the claim, or part of the claim, in accordance with the contract, (2) deny the entire claim, or part of the claim, and notify the provider why the claim will not be paid.

Payment is considered to have been paid on the date of: (1) the date of issue of a check for payment and its corresponding EOB to the provider by the MCO, or (2) electronic transmission, if payment is made electronically.

MCO must make every effort to avoid making more than one request to the provider for additional information in connection with a specific claim. MCO Claims procedures must include processes intended to prevent a provider claim from being repeatedly deficient-denied for reasons that were present on the original claim submission.

Whenever possible, the MCO should identify each applicable reason code and specific information requirements to inform the provider of the precise data fields and issues related to each claim. At minimum, MCO claim systems that employ a preset hierarchy of Deficient-Denial reasons, must provide sufficient information to the provider regarding the primary issue related to a claim.

The MCO must not pay any claim submitted by a provider excluded or suspended from the Medicare, Medicaid, CHIP, or CHIP Perinatal Programs for Fraud, Abuse, or Waste. The MCO must not pay any claim submitted by a provider who is on payment hold under the authority of HHSC or its authorized agent, or who has pending accounts receivable with HHSC.
MCOs must provide accurate and complete Encounter Data for pharmacy services. The Encounter Data must follow the format, rules, and data elements as described in the most current NCPDP Post-Adjudication Companion Guide and HHSC’s Encounter Submission Guidelines. The MCO should attest to the information prior to the MCO’s submission to HHSC. It is expected that MCO Pharmacy Claim Processing will comply with the requirements of the NCPDP B1/B2 HIPAA-compliant formats. This will produce consistent and verifiable data, whether self-reported by the MCO or produced by HHSC from the Encounter Data warehouse. The intent is to have uniform pharmacy claims data that can and will be verified both at the claims and Financial Statistical Report level, with the control file being the Encounter Data File.

If MCOs accept B3 claim transactions from pharmacies, the B3 transactions must be split into a B2 (reversal transaction) and B1 (new billing transaction) record on the encounter file provided to HHSC.

Pharmacy Encounter data provided to HHSC must include the following, in addition to the fields required on the NCPDP Post-Adjudication Companion Guide and HHSC’s Encounter Submission Guidelines:

1. The actual price paid by the MCO or its agent to the pharmacy for a drug, as well as the claim’s component dollar amounts (e.g., ingredient costs, dispensing fees, and amounts paid by other payors);
2. Adjudicated paid claims, including compounds;
3. MCOs must provide detailed line items for each ingredient in multi-ingredient compounds;
4. Adjudicated denied/rejected claims (only applies to edits identified by HHSC);
5. All fields as required by HHSC in the NCPDP post-adjudication format, including paid amounts and third-party payments;
6. An indicator if claim was subjected to Prior Authorization processing. If yes, then what type of processing—PDL, clinical, or both; and
7. An indicator if a claim was subject to Prior Authorization and was exempted. If yes, then identify the reason for the exemption (as described in the NCPDP Post-Adjudication file layout).

The MCO must notify the pharmacy provider in writing that the provider has 120 days from the date of disposition to appeal. The MCO must process appeals and adjudicate the claim within 30 days from the date of receipt. A provider may appeal any disposition of a claim.

The MCO’s subcontract with its Pharmacy Benefits Manager (PBM) must include a flow-down provision requiring the PBM to comply with the requirements of this section, including a requirement to disclose the actual and component prices paid by
the PBM to the pharmacy for each Encounter. PBM's must be held accountable for the required claims/encounter information.

B. Correction to a Paid Claim

NCPDP does not support a claim adjustment transaction in the D.Ø Standard, but corrections may be made to a clean claim. Once a claim has passed all edits, the payment amount reported to the pharmacy and the payment amount on that transaction may not be modified. Claim adjustments must be entered as a reversal transaction (B2) and a new billing transaction (B1).

C. Generic Substitution

A pharmacist may substitute a generically equivalent drug for the brand prescribed unless the prescriber writes in his/her own handwriting the words "Brand Necessary" or "Brand Medically Necessary" on the face of the prescription (42 C.F.R. § 447.331 and 22 Tex. Admin. Code § 309.3). For electronic prescriptions, the MCO must follow the NCPDP standard designation for “Dispense as Written (i.e., DAW = 1).” The prescriber must indicate on the electronic prescription that DAW = 1 and in the “Notes to the Pharmacy,” the prescriber must type “Brand Medically Necessary.” If the electronic prescription is received by the pharmacy with DAW = 1 without the corresponding message, the pharmacist must contact the prescriber for a new prescription. DAW = 1 is not required when the brand is preferred and the generic equivalent is non-preferred.

D. Health Resources Services Administration (HRSA) 340B

MCO's will identify if a pharmacy participates in the Health Resources Services Administration (HRSA) 340B discount drug program by referring to the HRSA Medicaid Exclusion file (http://opanet.hrsa.gov/opa/CEMedicaidExtract.aspx) on a quarterly basis. The file is updated on the 15th day of the month before the start of the each calendar quarter. The MCO must ensure that its pharmacy claims process recognizes claims from 340B pharmacies for products purchased through the 340B discount drug program. The only outpatient pharmacy drug claims that HHSC will exclude from the drug rebate system invoicing process are those that are submitted with a “2Ø” in Submission Clarification Code (Field 42Ø-DK). The SCC = 2Ø indicates that the pharmacy has filled the prescription using stock purchased through the HRSA 340B program. MCO's must inform and educate pharmacy providers that it is the responsibility of the provider to correctly report claims filled with 340B stock for 340B-eligible patients to ensure rebates are not collected for these drugs. MCO's must allow for the SCC = 2Ø indicator to be submitted on pharmacy claims. The MCO must ensure that the SCC = 2Ø indicator is included on the encounter.
The MCO must develop a policy for accepting and appropriately reimbursing claims for drug products purchased through the 340B discount drug program, and submit the policy to HHSC for review and approval. Any changes to the approved policy or reimbursement methodology must be prior approved by HHSC. MCOs must inform and educate pharmacy providers about its policy, notify pharmacy providers that adherence to the MCO’s and HHSC’s policies for 340B claims are subject to audit, and monitor 340B pharmacies to ensure claims are submitted appropriately. See the Vendor Drug Program Pharmacy Provider Procedures Manual for the HHSC policy.

E. Dual Eligible Members Medicaid Prescription Coverage for Outpatient Drugs and Biological Products

STAR+PLUS MCOs are responsible for providing outpatient drugs, biological products, certain limited home health supplies (LHHS), and vitamins and minerals as identified on the HHSC drug exception file marked with "MD" or "MB" as Medicaid covered services for STAR+PLUS Members. Dual Eligible Members are individuals who are entitled to Medicare Part A and/or Part B and eligible for some form of Medicaid benefit. Medicaid pharmacy benefits for Dual Eligible Members can be defined in one of the following three categories:

1. Pharmacy Coverage for Medicare Part B with Medicaid

HHSC’s drug exception file identifies the outpatient drugs, biological products, LHHS, and vitamins and minerals with "MB" that are payable by Medicare Part B for STAR+PLUS Members. STAR+PLUS MCOs are responsible to pay the cost sharing for outpatient drugs, biological products, and LHHS covered by Medicare Part B. See Attachment B.

If Medicare Part B provides a paid response, MCO should follow the guidelines below:

   a. The claim is received with a $0.00 paid amount; Medicaid will cover the cost share/co-insurance deductible.
   b. The claim is received with paid amount greater than $0.00, but less than the Medicaid allowed amount for identified drugs covered by Medicaid; Medicaid may cover the cost share portion up to the Medicaid allowed amount.

2. Medicare Part D with Medicaid – Wrap-Around Services

HHSC’s drug exception file identifies the outpatient drugs, biological products, LHHS and vitamins and minerals with "MD" covered by Medicaid for STAR+PLUS Members enrolled in Medicare Part D. STAR+PLUS MCOs must pay claims for these drugs and products for these members. If the Member is eligible for Medicare Part B and the drug or product is a covered benefit of Medicare Part B, the MCO
must validate Medicare Part B was billed in accordance with guidelines outlined in Section VI. E. 1. See Attachment C.

3. True Cross-over Claims

CMS states that individuals that are enrolled in Medicare Part A or Part B are also eligible for Medicare Part D. STAR+PLUS MCOs are responsible for validating the Medicare eligibility file and ensuring the pharmacy claims adjudicate as follows:

- If the client is eligible for Medicare Part D claims with a Medicare Part D covered drug and/or product must be billed to Medicare Part D and/or commercial insurance (if there is commercial insurance on file) prior to billing Medicaid.
- Medicaid must continue to pay (and no change in processing will occur) for Medicare Part D wrap-around drugs after commercial insurance has been billed or if there is no commercial insurance on file. These wrap-around drugs and products include non-prescription (over the counter medications), some products used in symptomatic relief of cough and colds, LHHS, some prescription vitamins and mineral products which are identified on the HHSC Drug Exception file.
- The cost-share (deductible, premium or co-pay) for Medicare Part B drugs and products after commercial insurance has been billed or if there is no commercial insurance on file.

If a client does not have Medicare Part D information on file or says that they are not enrolled in a Medicare Part D plan, the MCO should instruct the pharmacy to either:

- Bill the Medicare Limited Income (LI-NET) program, call LI-NET program at 800-783-1307 or visit the LI-NET Pharmacy portal at http://www.humana.com/pharmacists/resources/li_net.asp.
- Utilize the Facilitated Enrollment process to enroll the client in a plan by calling 800-633-4227, or;
- Call 1-800-MEDICARE (800-633-4227) for additional information.


Attachment A is a flowchart that MCOs may use as a reference for cost avoidance or coordination of benefits (COB) when processing claims that are covered by commercial insurance. In accordance with UMCC Section 8.2.2.2, family planning drugs are exempt from the COB process.

Attachments B and C are flowcharts that MCOs must use for processing Medicaid claims with Medicare Part B and Medicare Part D.

F. Flu Vaccines Provided in a Pharmacy
Effective May 15, 2014, MCOs have the option to allow pharmacies to bill for flu vaccines provided to adults aged 18 and older in a pharmacy setting.

The pharmacist administering the flu vaccine does not have to be enrolled with HHSC’s Claims Administrator or VDP, but must follow the Texas State Board of Pharmacy rules related to certification to immunize and vaccinate (22 Tex. Admin. Code § 295.15) and any other applicable law. The MCO must establish procedures for verifying that pharmacists administering vaccines have complied with the Texas State Board of Pharmacy’s certification requirements.

The MCO must follow these claims processing requirements:

- The pharmacy’s NPI must be submitted on the encounter. The MCO/PBM is encouraged to collect the administering pharmacist’s NPI.
- A “7” is required in the Submission Clarification Code field (Field 42Ø-DK) on the encounter to designate that the flu vaccine is non-formulary/medically necessary.
- The value “MA” in Field 44Ø-EF – Professional Service Code is required on the encounter to designate the service on the encounter.
- The pharmacy must submit a claim that includes the Professional Service Code (Field 44Ø-E5) with the value “MA” (Medication Administration) in the DUR/PPS segment for the service as well as the appropriate NDC for the flu vaccine in Product/Service ID (Field 4Ø7-D7).

The MCO is not required to offer all Medicaid-covered flu vaccines through a pharmacy if Members can access these vaccines through their PCP or other medical provider. Similarly, the MCO must not pay a pharmacy claim for flu vaccines that are not Medicaid-covered benefits.

Based on encounter data, HHSC will generate MCO vaccine expenditure reports to ensure proper accounting as a medical benefit.

G. Covered Drugs Under Non-Risk Payment

MCOs are responsible for providing certain drugs under non-risk, cost settlement basis, in accordance with UMCC Attachment A, Section 10.18, "Non-risk Payments for Drugs." The MCO must follow HHSC’s clinical review criteria located at www.txvendordrug.com to approve the provision of these drugs. Reimbursement by HHSC may be up to the Medicaid fee-for-service rate that HHSC would have paid for the drug on the date of service for a valid claim. The non-risk payments will cover only the cost of the drugs. Reasonable administrative costs associated with coverage of these drugs as well as adjunctive therapies if any associated with the treatment of these drugs will be part of the existing Capitation Rate. The MCO may not include the cost of the drugs in the Financial Statistical Report (FSR).
The identified covered drugs through a non-risk payment are:

a) Second generation direct acting antivirals (DAAs) for the treatment of Hepatitis C
b) Orkambi

H. Psychotropic Medication Utilization Review (PMUR)

As required in UMCC Section 8.1.21.6, the MCOs Drug Utilization Review process must specifically assess prescribing patterns for psychotropic medications. Below are the minimum requirements for retrospective psychotropic medication utilization review (PMUR). (See DFPS's website for more information: http://www.dfps.state.tx.us/Child_Protection/Medical_Services/guide-psychotropic.asp).

1. Each MCO PMUR process must include at a minimum the following DFPS parameters for Medicaid beneficiaries under the age of 18:
   
   - ≥ 4 psychotropic medication
   - ≥ 2 Stimulants
   - ≥ 2 Alpha agonist
   - ≥ 2 Antidepressants
   - ≥ 2 Antipsychotics
   - ≥ 3 Mood stabilizers
   - Dose exceeds usual recommended doses (literature based) (high dose)
   - ADHD/ADD treatment (stimulants) for < 3 years old
   - ADHD/ADD treatment (alpha agonists) for < 4 years old
   - Antidepressant for < 4 years old
   - Mood stabilizer for < 4 years old
   - Antipsychotic for < 5 years old

2. Compliance with the requirement for a "peer-to-peer discussion" may be achieved by a variety of outreach strategies, to include: letters to prescribers, phone calls to prescribers, and the opportunity for a prescriber to request a direct consultation with the plan. Peer-to-peer discussion is considered a form of outreach strategy and may be performed by a Medical Director, Behavioral Health Medical Director, designated clinical pharmacist, or other designated health care professional approved by HHSC.

The MCO must submit a Psychotropic Medication Utilization Review (PMUR) report beginning with Q1 of SFY 2017 and within 30 calendar days from the end of the quarter. The MCO must submit the PMUR report using the template contained in the UMCM Chapter 5.13.5.
I. Managed Care Clinical Prior Authorization Criteria Implementation

MCOs must submit a report to HHSC that lists all Clinical Prior Authorization (Clinical PA) criteria approved by the HHSC Drug Utilization Review (DUR) Board and indication whether the PA Criteria is being applied by the plan for each program. The MCO must submit a Clinical Prior Authorization Criteria Report on a quarterly basis, by the last day of the month following the reporting period using the template contained in UMCM Chapter 5.13.6.

VII. MESSAGES TO PHARMACIES

1. General Rejection Message Instructions

The MCO must use the additional NCPDP message field (526-FQ) as needed when the standard reject code provides insufficient information for the pharmacy to determine next steps, or the standard reject code is used for multiple criteria (e.g., excessive quantity, prescription limits have been met).

2. 72-hour Emergency Prescription Rejection Message (Required Language)

The following message must be returned to pharmacies on all electronically-submitted claims that the MCO rejects because the prior authorization criteria have not been met.

“Prescriber should call [insert hotline or call center name and number] or RPH [or PHARMD] should submit 72 HR Emergency Rx if DR not available.”

VIII. PERFORMANCE REQUIREMENTS AND TIMEFRAMES

HHSC may impose remedies, including liquidated damages, if the MCO or its Subcontracted Claims Processor does not Process and finalize claims according to the performance requirements and timeframes described in this Chapter and the Contract.

IX. INTEREST PAYMENTS

The MCO is subject to remedies, including liquidated damages, if the MCO does not pay providers interest at an 18% annual rate, calculated daily, for the full period in which the Clean Claim, or portion of the Clean Claim remains unadjudicated beyond the 18-day claims processing deadline if submitted electronically, or the 21-day claims processing deadline if submitted non-electronically.
The principal amount on which the interest payment will be calculated is the amount due but unpaid at the contracted rate for the service.

The MCO and its subcontracted Claims Processors must keep an accurate and sufficient audit trail for each interest payment and its corresponding claims documentation and provide a detailed report to HHSC upon request.

X. HEALTH INSURANCE PORTABILITY AND ACCOUNTABILITY ACT (HIPAA) COMPLIANCE

The MCO must comply with all HIPAA requirements as described in the contract. The MCO must comply with HIPAA EDI requirements in claims and remittance transactions in the NCPDP B1/B2 HIPAA-compliant formats.
Attachment A – COB Cost Avoidance Processing Flowchart

**Other Coverage Code (OCC) Values:**
- Ø = Not Specified By Patient
- 1 = No Other Coverage
- 2 = Other Coverage Exists – Payment Collected
- 3 = Other Coverage Billed – Claim Not Covered
- 4 = Other Coverage Exists – Payment Not Collected

**Rejected by Other Payer**
- OCC = 3
- and Other Payer Reject Code > 0

**$0 Paid by Other Payer**
- OCC = 4
- and Other Payer Amt Paid = $0

**Partially Paid by Other Payer**
- OCC = 2
- and Other Payer Amt Paid > $0

In accordance with UMCC Section 8.2.2.2, family planning drugs are exempt from the COB process.
Attachment B - Medicare Part B Pharmacy Claims Processing

[Diagram showing the process flow for Medicare Part B Pharmacy Claims Processing, including decision points for STAR+PLUS Dual Eligible Client, Part B Drug, and COB Info on Claim, with outcomes for Acceptable Reject Code, Pay in Full, and Reject Claim (Refer to Part B Plan).]
Attachment C - Medicare Part D Pharmacy Claims Processing

If a client does not have Medicare Part D information on file or says that they are not enrolled in a Medicare Part D plan, the MCO should instruct the pharmacy to either:
- Bill the Medicare Limited Income (LI-NEt) program, call LI-NEt program at 800-763-1307 or visit the LI-NEt Pharmacy portal at [https://www.humana.com/pharmacists/resources/li_net.asp](https://www.humana.com/pharmacists/resources/li_net.asp)
- Utilize the Facilitated Enrollment process to enroll the client in a plan by calling 800-633-4227, or;
- Call 1-800-MEDIcare (800-633-4227) for additional information.

"Wraparound drugs" are a Medicaid-only service that is meant to supplement the Medicare Part D benefit for clients enrolled in Part D and Medicaid.

HHSC’s drug exception file identifies the outpatient drugs, biological products, Lmhs, and vitamins and minerals with "MD" covered by Medicaid for STAR+PLUS Members enrolled in Medicare Part D. STAR+PLUS MCOs must pay claims for these drugs and products for these members.

MCO Drug Exception File
Part-D Wrap Drug = "MD" on Date of Service
Part-B Cost share = "MB" on Date of Service